Regeneron Pharmaceuticals, Inc.

Mastercard International Incorporated

Tong Zhang

Eric L Smith

Samuel H Davis

Chia-Yang Lin

Supriya Patel

Andrew J Murphy

Erica Pyles

Nina Liu

Michael Rosconi

Jiaxi Wu

Qian Wang

Thomas Craig Meagher

Maria Del Pilar Molina-Portela

Edward M Lee

Po Hu

Nicolin Bloch

Ramamohan R Sangasani

Chiayang Lin

Eric Smith

Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

Antigen binding molecule formats

The present disclosure relates to IL2 agonists with improved therapeutic profiles.

IL2 agonists and methods of use thereof

IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof

This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2Rα. The IL-2 variants may retain the ability in binding to or activating IL-2Rβ and/or IL-2Rγ. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

IL2 and peptide-MHC complex fusion proteins and methods of use thereof

This disclosure relates to IL-2 variants and methods of use thereof, including methods of treating or inhibiting a cancer or tumor. The IL-2 variants may have reduced ability in binding to or activating IL-2R&#x3b1;. The IL-2 variants may retain the ability in binding to or activating IL-2R&#x3b2; and/or IL-2R&#x3b2;&#x3b3;. In addition, the IL-2 variants may have decreased Treg activity but maintain the capacity to activate NK cells and T effector cells.

IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fc&#x3b3; receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fc&#x3b3; receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

Heavy chain constant regions with reduced binding to Fc gamma receptors

Health-related data is accessed; as is a database of payment card transaction data. At least a portion of the health-related data is linked to at least a portion of the payment card transaction data to obtain linked data. Statistical analysis is carried out on the linked data, and the results of the statistical analysis are made available to at least one appropriate party. Privacy is protected, for example, via an opt-in approach or through data aggregation.

Privacy-compliant analysis of health by transaction data

Growing community of inventors

Greenwich, CT, United States of America

Tong Zhang